Get the Stockscreener App
3.46
0.00%
0.00
After Hours:
3.49
0.03
+0.87%
Gossamer Bio Inc stock is traded at $3.46, with a volume of 4.24M.
It is up +0.00% in the last 24 hours and up +79.27% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
See More
Previous Close:
$3.46
Open:
$3.48
24h Volume:
4.24M
Relative Volume:
1.28
Market Cap:
$786.74M
Revenue:
-
Net Income/Loss:
$-179.82M
P/E Ratio:
-2.6015
EPS:
-1.33
Net Cash Flow:
$-159.16M
1W Performance:
+17.69%
1M Performance:
+79.27%
6M Performance:
+158.21%
1Y Performance:
+293.18%
1-Day Range:
$3.3591
$3.60
1-Week Range:
$2.61
$3.60
52-Week Range:
$0.6617
$3.60
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
3.46 | 707.15M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.50 Average Price Target from Brokerages - Defense World
RSI Crosses Above 30 for Gossamer Bio Inc. — Reversal in SightEarnings Recap Summary & Reliable Price Action Trade Plans - Newser
Can swing trading help recover from Gossamer Bio Inc. lossesPortfolio Value Report & Low Drawdown Trading Strategies - Newser
Gossamer Bio (NASDAQ:GOSS) Shares Gap UpTime to Buy? - MarketBeat
Gossamer Bio Sees Unusually High Options Volume (NASDAQ:GOSS) - MarketBeat
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.50 Average Price Target from Analysts - MarketBeat
What earnings revisions data tells us about Gossamer Bio Inc.2025 Key Lessons & Weekly High Potential Stock Alerts - Newser
Has Gossamer Bio Inc. found a price floorPortfolio Growth Summary & Accurate Buy Signal Notifications - Newser
Tick level data insight on Gossamer Bio Inc. volatilityTrade Volume Summary & Entry Point Strategy Guides - Newser
Using AI based signals to follow Gossamer Bio Inc.Quarterly Profit Report & Weekly High Conviction Ideas - Newser
Chart based analysis of Gossamer Bio Inc. trendsWeekly Stock Recap & Daily Profit Maximizing Tips - Newser
Combining machine learning predictions for Gossamer Bio Inc.Quarterly Investment Review & Weekly Watchlist of Top Performers - Newser
Detecting support and resistance levels for Gossamer Bio Inc.Quarterly Growth Report & Stepwise Trade Signal Guides - Newser
Is Gossamer Bio Inc. forming a bottoming baseQuarterly Growth Report & Free Safe Capital Growth Stock Tips - Newser
Analyzing recovery setups for Gossamer Bio Inc. investorsStop Loss & Verified Short-Term Trading Plans - Newser
Analyzing drawdowns of Gossamer Bio Inc. with statistical toolsNew Guidance & Smart Money Movement Alerts - Newser
How to recover losses in Gossamer Bio Inc. stockJuly 2025 Macro Moves & Daily Growth Stock Tips - Newser
Should you hold or exit Gossamer Bio Inc. nowEarnings Risk Report & Expert Approved Trade Ideas - Newser
Is Gossamer Bio Inc. building a consolidation basePortfolio Performance Summary & Stepwise Trade Execution Plans - Newser
Alyeska Investment Group L.P. Has $4.58 Million Holdings in Gossamer Bio, Inc. $GOSS - MarketBeat
What high frequency data says about Gossamer Bio Inc2025 Key Lessons & Fast Exit and Entry Trade Guides - Newser
Using Python tools to backtest Gossamer Bio Inc. strategiesQuarterly Growth Report & Daily Oversold Stock Bounce Ideas - Newser
How to manage a losing position in Gossamer Bio Inc.Weekly Market Report & Precise Entry and Exit Recommendations - Newser
H.C. Wainwright Asserts Buy Stance on Gossamer Bio Inc. (GOSS) on Pulmonary Arterial Hypertension Drug Prospects - Yahoo Finance
Cantor Fitzgerald reiterates Overweight rating on Gossamer Bio stock - Investing.com
What’s the recovery path for long term holders of Gossamer Bio Inc.2025 Investor Takeaways & Real-Time Chart Breakout Alerts - Newser
Gossamer Bio (NASDAQ:GOSS) Reaches New 52-Week HighHere's Why - MarketBeat
Will breakout in Gossamer Bio Inc. lead to full recoveryJuly 2025 Trends & Low Risk Profit Maximizing Plans - Newser
Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case - Insider Monkey
Can Gossamer Bio Inc. hit a new high this month2025 Top Gainers & Smart Allocation Stock Tips - Newser
Investors Purchase Large Volume of Gossamer Bio Call Options (NASDAQ:GOSS) - Defense World
Price momentum metrics for Gossamer Bio Inc. explained2025 Trading Volume Trends & Growth-Oriented Investment Plans - Newser
Sector ETF performance correlation with Gossamer Bio Inc.2025 Market WrapUp & Accurate Trade Setup Notifications - Newser
Short interest data insights for Gossamer Bio Inc.Weekly Volume Report & Low Risk Entry Point Tips - Newser
Technical analysis overview for Gossamer Bio Inc. stockMarket Performance Report & High Accuracy Trade Alerts - Newser
Gossamer Bio (NASDAQ:GOSS) Shares Down 6%Here's What Happened - MarketBeat
Gossamer Bio announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Gossamer Bio Shares Rise After UBS Upgrade, PT Increase - MarketScreener
Gossamer Bio’s Bold Progress: Buy or Pass? - StocksToTrade
Gossamer Bio stock upgraded at UBS (GOSS:NASDAQ) - Seeking Alpha
Gossamer Bio stock rating upgraded by UBS on PAH trial optimism - Investing.com
What moving averages say about Gossamer Bio Inc.Portfolio Performance Summary & Smart Money Movement Tracker - Newser
UBS Upgrades Gossamer Bio(GOSS.US) to Buy Rating, Raises Target Price to $9 - 富途牛牛
Using data models to predict Gossamer Bio Inc. stock movementTrade Risk Report & Fast Entry High Yield Stock Tips - Newser
How to use a screener to detect Gossamer Bio Inc. breakoutsQuarterly Performance Summary & Weekly Watchlist for Consistent Profits - Newser
How moving averages guide Gossamer Bio Inc. tradingJuly 2025 Momentum & Stepwise Entry/Exit Trade Alerts - Newser
Long term hold vs stop loss in Gossamer Bio Inc.Earnings Recap Report & AI Based Buy and Sell Signals - Newser
Using data filters to optimize entry into Gossamer Bio Inc.Earnings Recap Report & Weekly Top Gainers Alerts - Newser
What institutional flow reveals about Gossamer Bio Inc.2025 Investor Takeaways & Risk Controlled Stock Pick Alerts - Newser
What high frequency data says about Gossamer Bio Inc.2025 Risk Factors & AI Based Buy and Sell Signals - Newser
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):